Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

Sponsor
Guangxi Medical University
Study ID
NCT05062837
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

Study Details

This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR, DCR, DOR, TTP and PFS of patients receiving hepatectomy combined with apatinib + carrelli pearl treatment.

Key Dates

Start date
Jun 1, 2021
Status verified
Jan 2024
Primary completion
Sep 30, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
62 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hepatectomy Combined With Camrelizumab and Apatinib
    Patients with CNLC IIIb hepatocellular carcinoma will receive hepatectomy. Two to four weeks later, they will receive camrelizumab and apatinib treatments.

Primary Outcome Measure

Overall survival [ Time Frame: 2 years ]

Central Contacts

Related Studies